Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Epithelial SLPI expression in severe inflammatory bowel disease relates to high IL-17 and neutrophil programming
Sandrine Nugteren, Beatriz Calado, Ytje Simons-Oosterhuis, Daniëlle H. Hulleman-van Haaften, Willem K. Smits, Renz C.W. Klomberg, Bastiaan Tuk, Mohammed Charrout, Dicky J. Lindenbergh-Kortleve, Michail Doukas, Mathijs A. Sanders, Gregory van Beek, Johanna C. Escher, Lissy de Ridder, Maria Fernanda Pascutti, Janneke N. Samsom
Sandrine Nugteren, Beatriz Calado, Ytje Simons-Oosterhuis, Daniëlle H. Hulleman-van Haaften, Willem K. Smits, Renz C.W. Klomberg, Bastiaan Tuk, Mohammed Charrout, Dicky J. Lindenbergh-Kortleve, Michail Doukas, Mathijs A. Sanders, Gregory van Beek, Johanna C. Escher, Lissy de Ridder, Maria Fernanda Pascutti, Janneke N. Samsom
View: Text | PDF
Research Article Gastroenterology Immunology

Epithelial SLPI expression in severe inflammatory bowel disease relates to high IL-17 and neutrophil programming

  • Text
  • PDF
Abstract

Heterogeneity in disease severity and treatment response in inflammatory bowel disease (IBD) likely evolves from individual differences in host-microbiota-immune interactions. Histological evaluation of intestinal biopsies is central to diagnosis, but histological parameters that define underlying immune mechanisms are limited. We investigated histological features that distinguish individual patient immune profiles in therapy-naive pediatric IBD patients (age 6–18 years) using biopsy immunohistochemistry and transcriptomics and plasma proteomics across two cohorts. High colonic epithelial expression of secretory leukocyte protease inhibitor (SLPI), a microbiota-induced regulator of epithelial function, occurred in IBD patients with high clinical disease activity and more severe endoscopic and microscopic disease activity. SLPI expression was related to increased neutrophil infiltration, transcriptomic signatures of activation, and genes known to associate with therapeutic resistance. High SLPI colocalized with high densities of IL-17–secreting cells and was associated with high plasma concentrations of Th17-related immune proteins. Additionally, patients with high intestinal SLPI had an intrinsically different immunotype, in which circulating neutrophils exhibited altered transcription of genes involved in neutrophil granule formation, phagocytosis, oxidative phosphorylation, and interferon signaling. Thus, high colonic SLPI expression at diagnosis associates with severe IBD, increased IL-17A–neutrophil pathway responses, and altered transcriptomic wiring of circulating neutrophils.

Authors

Sandrine Nugteren, Beatriz Calado, Ytje Simons-Oosterhuis, Daniëlle H. Hulleman-van Haaften, Willem K. Smits, Renz C.W. Klomberg, Bastiaan Tuk, Mohammed Charrout, Dicky J. Lindenbergh-Kortleve, Michail Doukas, Mathijs A. Sanders, Gregory van Beek, Johanna C. Escher, Lissy de Ridder, Maria Fernanda Pascutti, Janneke N. Samsom

×

Figure 4

RNA sequencing reveals enrichment of immune activation and neutrophil and T cell infiltration pathways in paired colonic biopsies from patients with high SLPI IHC scores.

Options: View larger image (or click on image) Download as PowerPoint
RNA sequencing reveals enrichment of immune activation and neutrophil an...
(A) Two adjacent (paired) biopsies were collected from multiple ileal and colonic regions during endoscopy for therapy-naive patients with CD or UC and IBD-negative (IBD-neg) controls. One paired biopsy was used for histological analysis, and RNA sequencing was performed on the paired biopsy from the most affected ileal and colonic region per patient. The modified GHAS was used to define the most affected ileal and colonic region per patient. SLPI IHC scores of the most affected biopsy were used to classify patients as SLPIlow (negative IHC) or SLPIhigh (weak/strong IHC). RNA sequencing was performed on the paired biopsy from the most affected ileal and colonic region per patient. (B–F) Intestinal gene expression of SLPIhigh and SLPIlow groups; differentially expressed genes (DEGs) were defined as having an FDR-adjusted P value ≤ 0.05 and log2FC > 1 or < –1. (B) Transcripts per kilobase million (TPM) values for SLPI RNA in ileal and colonic biopsies from SLPIlow and SLPIhigh groups. (C) Top 15 of the 26 upregulated hallmark pathways from gene set enrichment analysis. (D–F) Z-scored TPM values for DEGs in colonic biopsies from patients in the SLPIhigh versus the SLPIlow group. Genes are ranked according to significance (lowest adjusted P value on top). Above the heatmaps, TPM values for EPCAM (as a measure of an epithelial signal) and CD45 (a hematopoietic cell signal), the dichotomized SLPI IHC score (SLPIhigh, SLPIlow), the modified GHAS score from the paired biopsy, and the diagnosis are shown. (D) The 51 upregulated genes of 200 in the gene set “hallmark TNFA signaling via NFKB” pathway (M5890) (69, 70). (E) The upregulated gene set for the “neutrophil signature” contains known neutrophil-associated genes selected by us. (F) The upregulated gene set for the “IL-17 signature” was compiled using multiple pathways (see Supplemental Methods). (G) TPM values of representative DEGs (upregulated, adjusted P value ≤ 0.05 and log2FC > 1) in colonic biopsies from the SLPIhigh versus the SLPIlow group.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts